耐药标志物TOPO和MT在宫颈鳞癌中的表达及意义

Research on drug-resistant marker TOPOⅡ and MT in cervical squamous cell carcinoma

目的:探讨子宫颈癌变过程中,耐药标志物TOPO和MT的表达特点,以指导子宫颈癌患者化疗方案制定和判断预后。方法:收集子宫颈切除及活检标本118例。以S-P免疫组织化学方法,显示TOPO和MT的表达水平。结果:TOPO在正常宫颈上皮中无阳性表达,在子宫颈上皮内瘤变(CIN)中阳性率为48.00%,在子宫颈鳞癌中阳性率为30.00%,3者间有显著性差异(P<0.01)。MT在正常宫颈中阳性率为7.69%,CIN中阳性率为28.00%,在宫颈鳞癌中阳性率为56.25%(P<0.01)。结论:TOPO及MT在正常宫颈、CIN、宫颈鳞癌中的阳性表达率有差异(P<0.01)。TOPO和MT的表达水平,在指导临床制订宫颈癌化疗方案的同时还可作为早期诊断宫颈癌或判断CIN预后的参考指标。

Objective:To explore expression of drug-resistance markers TOPOⅡ(Topoisomerase Ⅱ) and MT(metallothionein),in cervical squamous cell carcinoma.Methods:The tissue samples were collected from 118 cases of cervices. All the a samples were stained with SP immunohistochemistry. Results:The results showed that brown-yellow granules were located in cytoplasm or nucleis. In patients with cervical squamous cell carcinoma, positive expression of TOPOⅡ was found in 24 of 80 cases (30.00%), in CIN the positive expression of TOPOⅡ was 48.00%, while TOPOⅡ was not detected in any of the cases of normal cervical (0%) (P<0.01).In normal cervical epidermis positive expression of MT was only 7.69%, in CIN the positive expression of MT was 28.00% , in patients with cervical squamous cell carcinoma it was found in 45 of 80 cases (56.25%). The difference was statistically significant (P<0.01). The positive expression of TOPOⅡ or MT was similar among different differention of cervical squamous cell carcinoma (P>0.05) . Conclusion:The positive expression of MT and TOPOⅡ were different in normal cervix ,CIN and cervical squamous cell carcinoma (P<0.01). Exploring expression of drug-resistance markers TOPOⅡ and MT may optimize treating plan and improve chemotherapeutic effect,meanwhile it is useful in cervical squamous carcinoma diagnosis and prognosis evaluation in CIN.